iwCLL 2023 | The OxPLoreD study: T-cell type abundance and gene expression in early lymphoproliferative disorders
In this video, Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, discusses some preliminary data from the OxPLoreD study looking at patients with pre-malignant B-cell abnormalities not requiring treatment, such as monoclonal B-cell lymphocytosis and stage A chronic lymphocytic leukemia (CLL). Preliminary data from the single cell analysis of T-cells of these individuals has shown expansion of the T-cell subset TEMRA approximately 2 to 3 years prior to patients needing treatment due to malignancy development. This information may allow for identification of patients who are at high risk of progression to malignancy so that earlier treatment interventions can be put into place. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
We have another study which looks at the other end of the spectrum of CLL, which is patients with monoclonal B-cell lymphocytosis and or stage A CLL not requiring treatment. This is the OxPLoreD study. It’s a non-interventional study that performs prospective sample collection and data collection over a period of up to five years on patients with these pre-malignant conditions. And we have performed single cell analysis amongst many other analyses...
We have another study which looks at the other end of the spectrum of CLL, which is patients with monoclonal B-cell lymphocytosis and or stage A CLL not requiring treatment. This is the OxPLoreD study. It’s a non-interventional study that performs prospective sample collection and data collection over a period of up to five years on patients with these pre-malignant conditions. And we have performed single cell analysis amongst many other analyses.
So the data presented at this conference is an analysis of the T-cells of those patients with pre-malignant B-cell abnormalities using Site Seek which is a new form of single cell RNA seq analysis. What the analysis shows so far is an expansion in a specific T-cell subset called the TEMRA subset. And these expansions, we can see those up to 2 or 3 years prior to the actual progression when patients then go on to needing treatment.
So we think, although the data remains very preliminary, we think that both the expansion of TEMRA and then also their very specific gene expression profile might help us to, in future, identify patients who would benefit from earlier treatment intervention. So essentially giving us the immunology information, in addition to the genomic information, that we need to identify patients at high risk of progression to needing treatment.
Read more...
